Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01200875 · ClinicalTrials.gov registry record

Performance-Enhancing Effects of Platelet-Rich Plasma (PRP) Injections

A clinical trial, sponsored by Stanford University.

Completed
Registry status
25
Enrollment target

NCT01200875: Completed study, sponsored by Stanford University.

NCT01200875 is a clinical trial that has completed, run by Stanford University. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT01200875 has completed, sponsored by Stanford University.

COMPLETED
Registry status
25 participants
Enrollment target

Study Summary

Platelet-Rich Plasma (PRP) has been banned in competitive athletes because some people think it may enhance athletic performance. However, there is very little published research to support or undermine this point of view. The purposes of this study are: (1) To assess the effects of local platelet-rich plasma (PRP) therapy on systemic levels of growth factors with suspected or known performance-enhancing effects; and (2) To understand whether the effect of PRP therapy on these growth factors differs between intramuscular and intratendinous PRP injections. This research study is looking for 40 people who are receiving platelet-rich plasma therapy for a tendon or muscle injury. The study involves collecting seven blood samples (2 teaspoons each) from each patient, before and after the PRP treatment. Blood samples may be donated at any location of the patient's choosing, and participants will be paid for their time.

Interventions

  • PROCEDURE Ultrasound-guided platelet-rich-plasma (PRP) injection
  • PROCEDURE Platelet-Rich Plasma (PRP)

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2010-07
Est. Completion 2013-05
Stanford University

1,744 total trials

What the finished NCT01200875 record still lists

NCT01200875 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 25 participants, a relatively small participant target.

The record links to 0 conditions, and to 2 interventions - of which Ultrasound-guided platelet-rich-plasma (PRP) injection is the first listed.

NCT01200875 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01200875 about?

NCT01200875 is a clinical study titled "Performance-Enhancing Effects of Platelet-Rich Plasma (PRP) Injections". Platelet-Rich Plasma (PRP) has been banned in competitive athletes because some people think it may enhance athletic performance. However, there is very little published research to support or undermine this point of view. The purposes of this study are: (1) To assess the effects of local platelet-r...

What is the current status of trial NCT01200875?

This trial is currently completed. The enrollment target is 25 participants. The study started on 2010-07. Estimated completion is 2013-05.

What interventions are being tested in trial NCT01200875?

The interventions under investigation include: Ultrasound-guided platelet-rich-plasma (PRP) injection (PROCEDURE), Platelet-Rich Plasma (PRP) (PROCEDURE).

Who is sponsoring clinical trial NCT01200875?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01166854 · 25 participants

    Characterization of Familial Myopathy and Paget Disease of Bone

  • NCT01913106 · 25 participants · Phase 1

    HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer

  • NCT02138669 · 25 participants · NA

    Intacs Prescription Inserts for Keratoconus Patients

  • NCT02174549 · 25 participants · Phase 1

    Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01200875, the US trial registry maintained by the National Library of Medicine. NCT01200875 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.